Outcome of the 38th Annual General Meeting...
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bal Pharma Limited held its 38th Annual General Meeting on September 25, 2025, conducted through audio-visual means. At the meeting, shareholders adopted the audited standalone and consolidated financial statements for the financial year ended March 31, 2025. A dividend of Rs. 1.20 per equity share (on a face value of Rs. 10) was declared. Mr. Himesh Virupakshya was reappointed as Whole Time Director, Mr. Jatish Sheth was reappointed as Independent Director for a second 5-year term, and Mr. Parameshwar G Bhat was appointed as Secretarial Auditor for 5 years. Shareholders also approved the 'Bal Pharma Ltd – Employees Stock Option Plan – 2025'. The cost auditors' remuneration for FY 2025-26 was ratified, and the e-voting results will be announced separately after the Scrutinizer's report is received.
The 12% dividend and the approval of a new ESOP 2025 plan are shareholder-friendly moves that may be viewed positively. Reappointments of directors and the secretarial auditor are routine, while the ESOP could lead to future equity dilution. E-voting results are still awaited and may influence near-term sentiment.